Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2007
04/12/2007WO2007039075A2 Pde inhibitors and combinations thereof for the treatment of urological disorders
04/12/2007WO2007039058A2 Use of opioid receptor antagonists
04/12/2007WO2007039057A1 Cosmetic compositions comprising hydroxyfatty acids
04/12/2007WO2007038979A1 Effervescent metformin composition and tablets and granules made therefrom
04/12/2007WO2007038949A1 Pharmaceutical compositions for the treatment of inner ear disorders
04/12/2007WO2007038875A1 Ccr5 receptor antagonist molecules
04/12/2007WO2007038869A1 Aptamers comprising arabinose modified nucleotides
04/12/2007WO2007038867A1 Controlled-release oral dosage form
04/12/2007WO2007038865A1 Substituted quinolines as inhibitors of leukotriene biosynthesis
04/12/2007WO2007038859A1 Odcase inhibitors for the treatment of malaria
04/12/2007WO2007038855A1 Medical gel
04/12/2007WO2007038829A1 Method of drug design
04/12/2007WO2007024863A9 Methods and formulations for modulating lyn kinase activity and treating related disorders
04/12/2007WO2007023115A3 P38 map kinase inhibitors and methods for using the same
04/12/2007WO2007023115A2 P38 map kinase inhibitors and methods for using the same
04/12/2007WO2007022609B1 Pharmaceutical composition of morphine in ready-to-use injectable solution form and single dosage form of morphine for epidural or intrathecal administration
04/12/2007WO2007022415A3 Substituted 2-aminothiazoles for treating neurodegenerative diseases
04/12/2007WO2007022305A3 2-aminoimidazopyridines for treating neurodegenerative diseases
04/12/2007WO2007022268A3 Compounds and compositions as protein kinase inhibitors
04/12/2007WO2007020213A3 Thiazolyl piperidine derivatives useful as h3 receptor modulators
04/12/2007WO2007018956A3 Antidiabetic oxazolidinediones and thiazolidinediones
04/12/2007WO2007017585A3 Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds
04/12/2007WO2007017538A3 Method of obtaining amlodipine besylate
04/12/2007WO2007017264A3 Pyrrolopyridinederivatives as modulators of the cannabinoid receptor for the treatment of immune and inflammatory disorders
04/12/2007WO2007016385A3 Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
04/12/2007WO2007016292A3 Heterocyclic amides as biofilm modulators
04/12/2007WO2007016209A3 Pure 1,2-benzisoxazole-3-methane-sulfonic acid sodium salt and purification process
04/12/2007WO2007015812A3 Hiv reverse transcriptase inhibitors
04/12/2007WO2007015175A3 Use of pp-1 inhibitors to prevent missplicing events
04/12/2007WO2007015170A8 Synapse-specific proteins in glomeruli
04/12/2007WO2007015002A3 Novel crystalline iv form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form
04/12/2007WO2007014335A3 Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
04/12/2007WO2007012967A3 Combination of voriconazole and fluconazole
04/12/2007WO2007012670A3 Compounds derived from 5-benzylidene imidazolidine 2,4-dione and their use as mchr-1 antagonists
04/12/2007WO2007011958A3 Intraoral dosage forms of glucagon
04/12/2007WO2007011951A3 Purification of paricalcitol
04/12/2007WO2007011843A3 Prevention and treatment of ophthalmic complications of diabetes
04/12/2007WO2007011759A3 Inhibitors of mitotic kinesin
04/12/2007WO2007011720A3 Cyclopentane n-lower alkyl heptenamide-5-cis-2- (3alapha- hydroxy-5-phenylpentyl) -3, ?5-dihydroxy, [1alpha, 2beta, 3alpha, 5alpha] compounds as agents for lowering intraocular pressure
04/12/2007WO2007010138A3 N(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof
04/12/2007WO2007009720A3 Prodrugs of pyrazoline compounds, their preparation and use as medicaments
04/12/2007WO2007009711A3 Octahydropentalene-substituted pyrazoline compounds, their preparation and use as medicaments
04/12/2007WO2007009701A3 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
04/12/2007WO2007009055A3 Ester prodrugs of prostratin and related phorbol compounds
04/12/2007WO2007008942A3 Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases
04/12/2007WO2007008586A3 Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
04/12/2007WO2007006561A3 Improved crystalline form of the compound a-348441
04/12/2007WO2007005056A3 Platinum complexes with mononitrile-containing ligands
04/12/2007WO2007002214A3 Acyl guanidines as beta-secretase inhibitors
04/12/2007WO2006138230A3 The preparation and use of protease inhibitors
04/12/2007WO2006136580A3 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
04/12/2007WO2006136428A3 Method and composition to treat skin ulcers
04/12/2007WO2006135605A3 Formulation of a thienopyridine platelet aggregation inhibitor
04/12/2007WO2006134499A3 2-(1h-indolylsulfanyl)-aryl amine derivatives
04/12/2007WO2006134163A3 Novel tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain
04/12/2007WO2006134135A3 Nutritional method for elderly people
04/12/2007WO2006133707A3 Anti-cancer combination treatment and kit-of-part
04/12/2007WO2006131566A3 Oral ribavirin pharmaceutical compositions
04/12/2007WO2006128802A3 3-methanesulfonylquinolines as gaba-b enhancers
04/12/2007WO2006128057A3 Oral dosage forms comprising progesterone and methods of making and using the same
04/12/2007WO2006127913A3 Modulation of lmw-ptpase expression
04/12/2007WO2006125921A3 Antibody or antibody fragment coupled with an immunogenic agent
04/12/2007WO2006125781A3 Haloalkoxy-substituted salicylic anilides
04/12/2007WO2006125531A3 Thienopyridines
04/12/2007WO2006124813A3 Substituted 7, 8-dihydro-1h-pyrimido [4,5-b] [1,4] diazepin-4-amines as?kinase inhibitors
04/12/2007WO2006124692A3 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
04/12/2007WO2006121960B1 Methods and sequences to suppress primate huntington gene expression
04/12/2007WO2006120563A3 Antibacterial agents
04/12/2007WO2006120007A3 Production of glucosamine from plant species
04/12/2007WO2006119844A3 Controlled release oral drug delivery system
04/12/2007WO2006116221A3 Therapeutic combinations for the treatment or prevention of psychotic disorders
04/12/2007WO2006114401A3 Novel cyclic amines
04/12/2007WO2006110534A3 A process for preparing a crystalline form of halobetasol propionate
04/12/2007WO2006105058A3 Trihydroxy polyunsaturated eicosanoid derivatives
04/12/2007WO2006104889A3 Novel compounds
04/12/2007WO2006102232A3 Dosing regimes for trans-clomiphene
04/12/2007WO2006100595A3 Chewing gum compositions of varenicline
04/12/2007WO2006100281A3 Solubilized ibuprofen
04/12/2007WO2006099396A3 Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
04/12/2007WO2006094029A3 Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
04/12/2007WO2006091836A8 Formulations of ladostigil tartrate
04/12/2007WO2006084894A3 Use of tryptophan in combination with caffeine and taurine, foodstuff and beverage containing said combination
04/12/2007WO2006083417A3 Processes of making sesquiterpenoid tashironin, its analogs and their uses
04/12/2007WO2006078598A3 Mitotic kinesin inhibitors
04/12/2007WO2006074379A3 Methods and compositions involving esters of azelaic acid and other dicarboxylic acids
04/12/2007WO2006073726A3 Use of certain biphenyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms)
04/12/2007WO2006073514A3 Compositions, methods and kits for repressing virulence in gram positive bacteria
04/12/2007WO2006071564A3 Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
04/12/2007WO2006064033A3 Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
04/12/2007WO2006062683A3 Treatment and prevention of epilepsy
04/12/2007WO2006060382A3 Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
04/12/2007WO2006059357A3 Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization
04/12/2007WO2006055672A3 Methods and compositions for treating pain
04/12/2007WO2006050381A3 Antiviral composition
04/12/2007WO2006044486A3 Methods and compositions for the utilization and targeting of osteomimicry
04/12/2007WO2006040534A3 Method of detecting the presence or activity of g - protein coupled receptor 92 (gpr92)
04/12/2007WO2006029221A3 Anti-tumor compounds with angeloyl groups
04/12/2007WO2006021692A8 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
04/12/2007WO2006021458A3 Pyrimidine derivatives
04/12/2007WO2006020830A3 Bisaryl-sulfonamides